Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Completed GX-03 Stage 1/Phase 2a Trial: 59.3% of GX-03 Patients Achieved Clear or Almost Clear Skin After Four Weeks, Compared with 30.4% Receiving Vehicle
Larger Phase 2b Atopic Dermatitis Trial Continues, Informed by Findings from Completed Stage 1/Phase 2a
Building on GX-03 Momentum, Turn Therapeutics Accelerates Hidradenitis Suppurativa Trial with Enrollment Now Expected to Begin in First Quarter 2027
Former
Company Expects Cash to Fund Operations into Third Quarter of 2027, with Additional Tranches of Capital Available from Existing Facilities
Additional Stage 1/Phase 2a results show encouraging response in the full atopic dermatitis trial population
In
“The results from our full Stage 1 trial population give us an important look at how patients responded to GX-03 across a wide range of disease severity and extent,” said
The Stage 1/Phase 2a results also show improved separation between GX-03 and vehicle arm. Among patients who entered the trial with severe itch, 61.5% of those treated with GX-03 achieved clear or almost clear skin after four weeks, compared with 8.3% receiving vehicle. Additionally, 46.2% of GX-03 patients with severe itch achieved
The ongoing Phase 2b trial is evaluating GX-03 in 120–136 atopic dermatitis patients with severe itch (pp-NRS>7), across a range of skin involvement (
“The completed Stage 1 trial gives us a clearer picture of GX-03’s potential, particularly for patients with severe itching. We believe severe itch may also help strengthen confidence in an atopic dermatitis diagnosis, since other skin conditions can look similar on visual examination alone,” said
We are also accelerating patient enrollment in the planned Phase 2a trial of GX-03 for hidradenitis suppurativa (HS) which is now expected to begin in the first quarter of 2027, ahead of the previously announced second-quarter target. HS is a chronic, often debilitating inflammatory skin disease that causes painful lumps, abscesses, and, in more advanced cases, tunnels beneath the skin. It affects an estimated 900,0001 adults in the
The trial will be designed to evaluate the safety and efficacy of GX-03 in patients with HS. GX-03 is designed to combine anti-inflammatory activity with the bacterial membrane-disrupting properties of its proprietary formulation. This dual approach may be particularly relevant to HS, where bacteria may contribute to persistent inflammation and recurrent lesions. By potentially addressing both processes directly at the affected skin, GX-03 could offer patients a differentiated, non-systemic treatment option. Treatment duration and assessment timepoints are being finalized.
With HS enrollment beginning and our Phase 2b atopic dermatitis trial moving forward, we expect the first quarter of 2027 to be a very active time for Turn.
Onychomycosis program
Onychomycosis, commonly known as nail fungus, affects an estimated 10% of the general population and up to 50% of adults over 702. GX-03 has shown that it can penetrate the nail and reduce fungal burden in animal studies which, coupled with independent investigator-sponsored human evidence, supports its continued development to test its efficacy as a potential topical treatment for fungal nail infections.
|
1 Epidemiology of hidradenitis suppurativa": https://www.sciencedirect.com/science/article/pii/S0738081X23000998 |
|
2 Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–770. |
New published research offers clues about how GX-03 may reduce inflammation and itching
In
Company appoints former
On
Recent investor presentations
On
On
Third Quarter 2026 Financial Results
The following highlights summarize the Company’s cash position and spending for the third quarter of 2026:
-
Cash and Cash Equivalents: The Company had
$10.4 million in cash and cash equivalents as ofSeptember 30, 2026 . Based on current estimates, the Company expects its available cash to support the ongoing Phase 2b atopic dermatitis trial and planned Phase 2a HS trial, with operations funded into the third quarter of 2027. -
General and Administrative (G&A) Expenses: G&A expenses for the three months ended
September 30, 2026 were$1.4 million , a decrease of$0.4 million compared to$1.8 million for the three months endedSeptember 30, 2025 . -
Research and Development (R&D) Expenses: R&D expenses were
$0.6 million for the three months endedSeptember 30, 2026 , an increase of$0.4 million compared to$0.2 million for the same period in 2025, reflecting continued spend on Phase 2b for atopic dermatitis. -
Net Loss: Net loss for the three months ended
September 30, 2026 was$6.2 million , or$(0.21) per basic and diluted share, compared to$1.9 million , or$(0.07) per basic and diluted share, for the same period in 2025.
|
Financial Tables
Condensed Consolidated Statements of Operations (Unaudited, in US Dollars) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months
|
|
|
Nine Months
|
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General and administrative |
|
$ |
1,379,245 |
|
|
$ |
1,754,856 |
|
|
$ |
3,637,573 |
|
|
$ |
3,434,442 |
|
|
Research and development |
|
|
605,197 |
|
|
|
158,699 |
|
|
|
1,189,697 |
|
|
|
230,636 |
|
|
Total operating expenses |
|
|
1,984,442 |
|
|
|
1,913,555 |
|
|
|
4,827,270 |
|
|
|
3,665,078 |
|
|
Loss from operations |
|
|
(1,984,442 |
) |
|
|
(1,913,555 |
) |
|
|
(4,827,270 |
) |
|
|
(3,665,078 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from change in fair value of derivative liability instrument |
|
|
(3,343,491 |
) |
|
|
- |
|
|
|
(5,987,498 |
) |
|
|
- |
|
|
Amortization of deferred offering and financing costs |
|
|
(640,122 |
) |
|
|
- |
|
|
|
(1,756,520 |
) |
|
|
- |
|
|
Interest expense |
|
|
(341,208 |
) |
|
|
- |
|
|
|
(703,502 |
) |
|
|
- |
|
|
Interest income |
|
|
83,973 |
|
|
|
5,111 |
|
|
|
223,057 |
|
|
|
15,408 |
|
|
Other income (expense) |
|
|
(5,578 |
) |
|
|
4,260 |
|
|
|
- |
|
|
|
176,520 |
|
|
Total other income (expense) |
|
|
(4,246,426 |
) |
|
|
9,371 |
|
|
|
(8,224,463 |
) |
|
|
191,928 |
|
|
NET LOSS |
|
$ |
(6,230,868 |
) |
|
$ |
(1,904,184 |
) |
|
$ |
(13,051,733 |
) |
|
$ |
(3,473,150 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share |
|
$ |
(0.21 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.44 |
) |
|
$ |
(0.13 |
) |
|
Weighted-average common shares outstanding, basic and diluted |
|
|
30,137,336 |
|
|
|
27,975,207 |
|
|
|
29,802,800 |
|
|
|
27,479,246 |
|
|
Selected Balance Sheet Data (in US Dollars) |
||||||||
|
|
||||||||
|
|
|
|
|
|
|
|
||
|
|
|
2026 |
|
|
2025 |
|
||
|
|
|
(Unaudited) |
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
10,363,975 |
|
|
$ |
5,076,144 |
|
|
Total assets |
|
|
16,349,722 |
|
|
|
12,162,241 |
|
|
Total liabilities |
|
|
10,657,545 |
|
|
|
7,475,518 |
|
|
Total stockholders’ equity |
|
|
5,692,177 |
|
|
|
4,686,723 |
|
About GX-03
GX-03 is Turn Therapeutics’ proprietary, non-systemic topical formulation. The formulation is based on the same core formula used in Turn Therapeutics’ prior,
About Turn Therapeutics
Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious dermatologic diseases. Its lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for hidradenitis suppurativa and onychomycosis. For more information, visit www.turntherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, anticipated financial results, cash runway, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and Turn Therapeutics’ ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in its filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn Therapeutics undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261109969887/en/
Investor Relations / Media Contact:
Sasha Damouni
Damouni Group LLC
sasha@turntherapeutics.com
Source: Turn Therapeutics Inc.